Stereoselectivity and Species Difference in Plasma Protein Binding of KE-298 and Its Metabolites
In vitro protein binding of KE-298 and its plasma metabolites, deacetyl-KE-298 (M-1) and S-methyl-KE-298 (M-2), was high in rat (Ͼ97%), dog (Ͼ89%) and human plasma (Ͼ99%), respectively. Human serum albumin (Ͼ93%) was the main protein involved in the binding to plasma proteins, while the binding to human serum globulins was low (16-33%). The binding of KE-298 and its metabolites in all species of plasma was stereoselective. The (؉)-(S)-enantiomers of these compounds bound rat, dog and human plasma proteins to a greater extent than did the (؊)-(R)-enantiomers, except that the case of KE-298 was opposite in rat plasma. The stereoselective plasma levels of these compounds in rats, dogs, or humans would likely be due to stereoselective differences in binding to plasma albumin. The protein binding of M-1 in adjuvant-induced arthritis rat plasma was Ͼ97%, and the stereoselectivity was similar to the case of normal rat plasma. KE-298 and its metabolites remarkably displaced [ Co., Ltd. (Ibaraki, Japan)) ate pellet food (DS, Oriental Yeast Co., Ltd.) once daily, and water was freely available for drinking.
Six healthy male volunteers, aged from 20 to 23 years (mean age, 22.2 years), with a mean weight of 59.6Ϯ2.8 kg, participated in the pharmacokinetic study of KE-298. All subjects had normal clinical laboratory profiles and physiological examinations. For in vitro protein binding experiments, 15 other healthy volunteers (8 men and 7 women), between the ages of 26 and 43 years, participated.
Dose Preparation and Administration of the Drug To study the plasma levels of KE-298 and its metabolites, a single oral dose of 5 mg/kg of racemic KE-298 suspended in 5% gum arabic was given to 3 male Wistar rats and 3 dogs. Six healthy volunteers were given a tablet containing 100 mg of racemic KE-298. All animals and volunteers were fasted 14-17 h before and 4 h after oral administration of the drugs.
Collection of Plasma and Analytical Procedures After oral administration of racemic KE-298 to rats, whole blood was withdrawn periodically from the inferior aorta into heparinized containers, following anesthetization with ether. In the case of dogs and humans, blood was taken from the antebrachial vein into heparinized containers, at predetermined times. Plasma was obtained by centrifugation of the blood samples.
The concentrations of racemic KE-298, M-1 and M-2 were measured, according to a previously described method.
14)
The (ϩ)-(S)/(Ϫ)-(R) ratios of KE-298 and its metabolites in plasma were analyzed using the chiral-HPLC system, according to a previously described method.
16) The concentration of each enantiomer was calculated by multiplying both the concentration of the racemate and the (ϩ)-(S)/(Ϫ)-(R) ratio.
Adjuvant-Induced Arthritis Rats Adjuvant arthritis was induced in female SD rats, according to a previously described method. 17) Blank plasma was collected 10 d after inoculated heat killed Mycobacterium butyricum.
In Vitro Protein Binding Rat, dog and human blood samples were collected without dosages, as described above, and blank plasma was obtained by centrifugation. HSA, abglobulins, g-globulin and M-1 diacetoneamine base were dissolved in saline. KE-298 and M-2 were dissolved in 1.77% KH 2 PO 4 -3.56% Na 2 HPO 4 · 12H 2 O isotonic phosphate buffer (pH 7.4). Each plasma or protein solution was pre-incubated for 3 min at 37°C, and each solution of drug was added, followed by incubation for 5 min at 37°C. The sample was added to ultrafiltration units, MPS-3 (Amicon, MA, U.S.A.) and centrifuged at 1000 g at 25°C until definite filtrates were obtained. Preliminary experiments showed that the membrane of MPS-3 did not exhibit any nonspecific adsorption of KE-298 and its metabolites. The concentrations of KE-298, M-1 and M-2 in plasma or protein solution and ultrafiltrate were analyzed using HPLC, as described below.
To 50 ml of plasma or protein solution, 10 ml of 2 M hydrochloride was added, then the mixture was left for 10 min at room temperature; thereby M-1 was converted to the stable dihydrothiophen form. After neutralization by adding an equal volume of 2 M sodium hydroxide, internal standard KE-456 and 150 ml of methanol were added to the sample, and 50 ml of extract was injected onto the HPLC. In the case of the filtrate (50 ml), 10 ml of 0.5 M hydrochloride was added, then the mixture was left for 30 min at room temperature. This preparation was neutralized with an equal volume of 0.5 M sodium hydroxide, and internal standard KE-456 was added, then 50 ml of aliquot was injected onto the HPLC. The condition of HPLC involved the use of a Wakosil-II5C18RS column, 4.6 mm i.d.ϫ150 mm (Wako Pure Chemical Industries, Ltd., Osaka, Japan), the flow rate was 1 ml/min, and UV detection was at 252 nm. When KE-298 in a solution of HSA or g-globulin was measured, the mobile phase was 50 mM phosphate buffer (pH 4.8)/acetonitrile (7 : 3, v/v), and the column temperature was set at 40°C. In other measurements, 20 mM phosphate buffer (pH 5.5)/acetonitrile (3 : 1, v/v) was used as the mobile phase and the column temperature was set at 25°C.
The extent of protein binding (%) was calculated according to:
% bindingϭ(1Ϫconcentration in ultrafiltrate /concentration in plasma or protein solution)ϫ100
Characterization of Albumin Binding Sites Effects of KE-298 and its metabolites on the displacement of [
14 C]warfarin, [ 14 C]diazepam or [ 3 H]digitoxin bound at the binding sites on RSA, DSA or HSA were measured, according to a previously described method.
16)

Pharmacokinetic Parameters and Statistical Analysis
The results are expressed as the mean values and standard errors. The value of the area under the level-time curve (AUC 0-8 h ) was calculated by the trapezoidal method. The elimination half-life (t 1/2 ) was calculated from the log-linear part of the plasma level-time curve. All statistical calculations and tests were done using the SAS/STAT package. Comparison between the protein binding of each enantiomer of KE-298 and its metabolites was assessed using Tukey's multiple comparison test. Student's test was used to compare the findings in 2 groups. The significance level for all tests was pϽ0.05. 
RESULTS
Plasma Levels
Plasma levels of each enantiomer of KE-298, M-1 and M-2 after the oral administration of racemic KE-298 to rats, dogs or humans and their estimated pharmacokinetic parameters are shown in Fig. 2 and Table 1 . Plasma levels of unchanged KE-298 increased rapidly in all species, but were extremely low and swiftly eliminated. M-1 was detected as the main metabolite. The level of M-2 was low but continuous in dogs and humans and was relatively high in rats. In rats, the AUC 0-8 h of (Ϫ)-(R)-KE-298 was approximately twice that of (ϩ)-(S)-KE-298. On the other hand, for both M-1 and M-2, the AUC 0-8 h of (ϩ)-(S)-enantiomers were about 8 and 11 times greater than those of (Ϫ)-(R)-enantiomers. The t 1/2 for M-1 and M-2 was shorter for (Ϫ)-(R)-enantiomers than for (ϩ)-(S)-enantiomers, and this was reversed in the case of KE-298 enantiomers. In dogs and humans, the (ϩ)-(S)/(Ϫ)-(R) ratios of the AUC 0-8 h of KE-298 were 30 and 2, while those of M-1 were 17 and 12, respectively. In the case of M-2, the level of the (Ϫ)-(R)-enantiomer was higher than the (ϩ)-(S)-enantiomer at an early time after administration, then later it was reversed. The AUC 0-8 h of (ϩ)-(S)-M-2 was greater than that of (Ϫ)-(R)-M-2. The t 1/2 for (Ϫ)-(R)-enantiomers of all compounds was shorter than that for (ϩ)-(S)-enantiomers.
Specific Difference in in Vitro Protein Binding In vitro binding of KE-298 and its metabolites was high, with over 97% bound in rat plasma and over 99% bound in human plasma at concentrations ranging from 5 to 100 mg/ml (Tables 2-4). The binding in dog plasma, with more than 89% bound, was slightly lower than that determined in rat and human plasma. The binding value of KE-298 and its metabo- 
Rat ( lites in solution of HSA was high, with 97% or higher at concentrations ranging from 5 to 20 mg/ml, similar to findings in human plasma. In all species of plasma and solution of HSA, the bound fraction of KE-298 and its metabolites tended to decrease at higher drug concentrations; this was remarkably observed in dog plasma and the solution of HSA. KE-298 and its metabolites at a concentration of 20 mg/ml bound approximately 30% with ab-globulins and approximately 20% with g-globulin, respectively. The protein binding of each enantiomer of KE-298, M-1 and M-2 was investigated in rat, dog and human plasma and the solution of HSA at a concentration of 20 mg/ml (Table 5) .
Stereoselective protein binding of these compounds was observed for all species concerning plasma and the solution of HSA. In the case of rat plasma, the protein binding of M-1 and M-2 was greater for (ϩ)-(S)-enantiomers than for (Ϫ)-(R)-enantiomers. In contrast, (Ϫ)-(R)-KE-298 bound to a greater extent than did (ϩ)-(S)-KE-298. On the other hand, in all cases of dog plasma, human plasma and the solution of HSA, the protein binding of the (ϩ)-(S)-enantiomer of KE-298 and its metabolites was greater than that of the (Ϫ)-(R)-enantiomer.
In Vitro Protein Binding in Adjuvant-Induced Arthritis Rat Plasma The concentration of albumin in the plasma of normal rats and adjuvant-induced arthritis rats was 31.4Ϯ1.5 and 16.7Ϯ1.6 mg/ml, respectively. The protein binding of each enantiomer of M-1 at a concentration of 40 mg/ml in adjuvant-induced arthritis rat plasma was a little lower than that in normal rat plasma, but the (Ϫ)-(R)/(ϩ)-(S) ratio of unbound fraction was not clearly affected ( On the other hand, the negligible displacement of [ 3 H]digitoxin was observed in all species. The same patterns were detected for both M-1 and M-2. No stereoselectivity was found in the displacement of the labeled marker by enantiomers of KE-298 and its metabolites.
DISCUSSION
Plasma levels of each enantiomer of KE-298 and its active metabolites after the oral administration of racemic KE-298 were investigated. M-1, deacetyl-KE-298 was the primary product, which underwent further methylation to M-2, Smethyl-KE-298. 14) In previous work, no significant stereoselectivity was observed in the metabolic rates of KE-298 enantiomers in vitro, using isolated rat hepatocytes. 15) In analbuminemic rats, no evidence of stereoselectivity was found for blood level-time profiles or plasma protein binding after the oral administration of (ϩ
)-(S)-and (Ϫ)-(R)-[
14 C]KE-298. 15) These results suggested that the stereoselective pharmacokinetics of KE-298 and its metabolites depend on plasma protein binding. We reported that undirectional metabolic chiral inversion from the (Ϫ)-(R)-to (ϩ)-(S)-enantiomer of M-2 occurred in rats, whereas no inversion was detected for KE-298 and M-1. 16) In dogs, chiral inversion was not detected in any compounds (unpublished data), and it was not studied in humans. Therefore, (ϩ)-(S)-M-2 in rat plasma would contain both (ϩ)-(S)-M-1 which had been metabolized and inverted (Ϫ)-(R)-M-2.
Species differences in protein binding have been studied regarding many drugs. [18] [19] [20] In the present study, in vitro binding of KE-298 and its plasma metabolites, M-1 and M-2, to rat, dog and human plasma proteins was high, and species differences were observed. The extent of binding of KE-298 and its metabolites to albumin exceeded that to globulins, and the binding to albumin approximated that in plasma at the concentrations in vivo (5-20 mg/ml). These results suggest that albumin is the major binding component in plasma for KE-298 and its metabolites, similar to findings with common acidic compounds, 8, 9, 21) hence globulins may have a small role in binding. On the other hand, after albumin was saturated in binding with high concentrations (100 mg/ml) of KE-298 and its metabolites, the compounds were able to bind other proteins, including globulins. Therefore, in the case of human plasma, the decrease in binding at a high concentration of KE-298 and its metabolites might be minor, compared with HSA.
It has been reported that there are species differences in stereoselective binding in some chiral drugs. 22, 23) The protein binding of each enantiomer of KE-298 and its metabolites showed stereoselectivity. These results explain the stereoselectivity of plasma level-time profiles of KE-298 and its metabolites after the oral administration of KE-298 to rats, dogs and humans, as described above.
In patients with rheumatoid arthritis, the concentration of serum albumin was decreased, compared to healthy subjects. 24) Therefore, the protein binding of each enantiomer of M-1 in adjuvant-induced arthritis rat plasma was investigated. The protein binding of M-1 was high, and their stereoselectivity was similar to the case of normal rats.
Binding sites on serum albumin of each enantiomer of KE-298 and its metabolites were investigated. Glibenclamide, indomethacin, naproxen and tolbutamide have a high-affinity to both warfarin and diazepam binding sites on HSA.
10) It was reported that the carboxyl group attached to the chiral carbon of arylpropionic acids binds the diazepam binding site, while the non-carboxyl group, the ester form of 804 Vol. 24, No. 7 
The experiments were done in duplicate. arylpropoinic acid or the hetero aromatic molecule binds the warfarin binding site. 25, 26) KE-298 and its metabolites have both the carboxyl group and the non-carboxyl group in their molecules. Consequently, KE-298 and its metabolites might bind at both the diazepam and warfarin binding sites. Kosa et al. reported that species differences are present in the binding sites on albumin. 27) In case of RSA, the binding affinity of warfarin is reasonably similar to HSA but the binding parameter of diazepam is apparently different; furthermore, the binding parameter for warfarin to DSA is significantly different from that to RSA and HSA. 27) Therefore, it was considered that differences in binding sites and affinity of KE-298 and its metabolites among RSA, DSA and HSA can be explained by species differences regarding binding sites on albumin. As described above, the protein binding of KE-298 and its metabolites was highly stereoselective between their enantiomers. Further, it was clarified that stereoselectivity was not due to binding to different binding sites on albumin. Drayer et al. reported that several chiral drugs showed stereoselective binding to the same binding sites.
13) The R-enantiomer of 3-methyldiazepam binds the diazepam binding site on HSA, to a much greater extent than the S-form. 13) In the case of warfarin itself, S-warfarin is highly bound, more so than R-warfarin. 13) Similarly, these binding sites may distinguish between the (ϩ)-(S)-and (Ϫ)-(R)-enantiomers of KE-298 and its metabolites.
In conclusion, it was noted that stereoselectivity in the protein binding of KE-298 and its metabolites affected pharmacokinetics in rats, dogs and humans, and that the stereoselective protein binding depended on quantitative differences in the same binding sites. In addition, species differences in protein binding of KE-298 and its metabolites were clarified, as related to species differences concerning the binding sites on albumin.
